Related Experiment Videos
Biochemotherapy for advanced melanoma.
1Oncology Center, Hospital Sirio-Libanes, Rua Adma Jafet 91, São Paulo, SP 01308-050, Brazil. buzaid@attglobal.net
Critical Reviews in Oncology/Hematology
|October 26, 2002
Summary
Biochemotherapy, combining chemotherapy with interleukin-2 and interferon-alpha, shows promise for metastatic melanoma. However, phase III trials require further investigation to confirm efficacy and long-term survival benefits.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Metastatic melanoma treatment remains challenging.
- Biochemotherapy (cisplatin, IL-2, IFN-α) demonstrated early promise.
- Previous phase II studies reported significant response rates.
Purpose of the Study:
- To evaluate the efficacy of biochemotherapy in metastatic melanoma.
- To identify factors influencing treatment outcomes.
- To inform the design of future clinical trials.
Main Methods:
- Review of phase II and III clinical studies.
- Analysis of response rates and survival data.
- Exploration of reasons for inconsistent phase III results.
Main Results:
- Phase II studies showed 40-60% overall response rates.
- Durable complete remissions observed in ~10% of patients.
- Phase III studies yielded inconsistent outcomes.
Conclusions:
- Biochemotherapy shows potential but requires further validation.
- Methodological factors may explain discrepancies between study phases.
- Ongoing large randomized trials are crucial for determining long-term impact.